Chemomab Therapeutics Ltd.

CMMB

$2.27

+$0.57 (33.53%)

Closed

No clear catalyst identified for CMMB's 25%+ surge on July 2

Loading chart...

IndexN/A

Market Cap0.01B

Enterprise Value0.00B

Income$-0.00B

Sales$0.00B

EmployeesN/A

P/E-1.40

P/SN/A

P/B0.85

P/C-0.94

EV/EBITDA-0.31

EV/SalesN/A

EPS (ttm)-1.62

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume1.34M

Shs Outstand0.01B

Change33.53%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

May 1408:00AMChemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update(globenewswire.com)

Mar 1908:00AMChemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update(globenewswire.com)

Feb 1708:00AMChemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference(globenewswire.com)

Jan 1504:52AMChemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest

Insider Trading

View All

Insider

Type

Price

Value

Date

Melincoff Gwen A

—

8.6K

$1.86

$16K

Jun 1, 26

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

CEO: Adi Mor GeorgeEmployees: 20www.chemomab.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$53.25K	$66.83K	$57.77K	$34.02K	$80.00K	$282.00K	$65.78K	$51.00K
Gross Profit	$-53.25K	$-66.83K	$-57.77K	$-34.02K	$-80.00K	$-282.00K	$-65.78K	$-51.00K
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$14.69M	$25.39M	$28.48M	$12.33M	$5.89M	$19.33M	$12.97M	$9.34M
Operating Income	$-14.74M	$-25.46M	$-28.53M	$-12.37M	$-5.97M	$-19.61M	$-13.04M	$-9.39M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-13.95M	$-24.22M	$-27.65M	$-12.48M	$-5.95M	$-27.21M	$-13.80M	$-9.81M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-3.12	$-8.22	$-9.68	$-4.80	$-25.21	$-63.20	$-87.09	$-875.98
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Chemomab Therapeutics Ltd.

Insider Trading

Discover more